This article was originally published in The Gray Sheet
One-time charge of $622 mil. will be recorded in the second quarter in anticipation of a settlement of civil and criminal charges related to sales and marketing practices by the firm's Ross Products enteral nutrition division. The charges stemmed from an industry-wide investigation of the enteral nutrition sector, initiated in the mid-1990's by the U.S. Attorney's office in the Southern District of Illinois. The investigation reportedly involved allegations of kickbacks in the form of discounted or free enteral pumps being supplied in exchange for disposable pump set supply contracts with providers; charges for such pumps may have been passed on to Medicare and Medicaid. "The anticipated settlement will resolve all outstanding allegations by the government," including "all federal and state Medicare and Medicaid issues," Abbott says June 26. Headquartered in Columbus, Ohio, Ross drew $688 mil. in earnings last year on $2.1 bil. in sales...
You may also be interested in...
Abbott's Ross Products unit will retain an independent review organization to oversee sales and marketing of enteral nutritional pumps and related disposables under a 1corporate integrity agreement between Abbott and the HHS Office of Inspector General
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.